While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

Alignment Healthcare raises its 2026 outlook as membership and medical-cost trends improve, but heavier second-half investments could pressure near-term profitability.

Alignment Healthcare lifted its 2026 outlook after 31%+ membership and revenue growth, but rich earnings valuation and second-half risks may justify a wait-and-see approach.

Alignment Healthcare (ALHC) is under pressure after a whistleblower lawsuit prompted several law firms to investigate claims that the company misclassified operating expenses as capital expenditures, which allegedly distorted adjusted EBITDA and investor perceptions. See our latest analysis for Alignment Healthcare. The whistleblower allegations and subsequent law firm investigations have landed on a stock that was already under pressure, with Alignment Healthcare’s 30 day share price return...

Alignment Healthcare (ALHC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Shares of health insurance company Alignment Healthcare (NASDAQ:ALHC) fell 14.8% in the afternoon session after the company revealed plans to reinvest profits, which will lower its expected earnings for the second half of the year.

Health insurance company Alignment Healthcare (NASDAQ:ALHC) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 31.6% year on year to $1.34 billion. The company expects next quarter’s revenue to be around $1.31 billion, close to analysts’ estimates. Its non-GAAP profit of $0.25 per share was 24.3% above analysts’ consensus estimates.

Alignment Healthcare Inc (ALHC) reports 31% membership growth and 32% revenue increase, while raising full-year 2026 guidance despite planned second-half investments.

Health plan membership surged 31% as AI-powered care coordination drove margin expansion.

The headline numbers for Alignment Healthcare (ALHC) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Alignment Healthcare (NASDAQ:ALHC) reported second-quarter growth in membership, revenue and adjusted EBITDA, while raising the low end of its full-year profitability outlook and increasing its membership expectations for 2026. Chairman and CEO John Kao said health plan membership reached 294,100 a

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of +30.77% and +1.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Health insurance company Alignment Healthcare (NASDAQ:ALHC) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 31.6% year on year to $1.34 billion. The company expects next quarter’s revenue to be around $1.31 billion, close to analysts’ estimates. Its GAAP profit of $0.17 per share was 29.8% above analysts’ consensus estimates.

PACS vs. ALHC: Which Stock Is the Better Value Option?

Health insurance company Alignment Healthcare (NASDAQ:ALHC) will be announcing earnings results this Thursday afternoon. Here’s what to expect.

Alignment Healthcare stock has surged over the past three years, yet the recent pullback and a strong overall value score raise a clear question about whether the current price still reflects what investors are paying for the underlying business and its risks. Alignment Healthcare has delivered a 237.9% return over the past three years, which puts recent short term weakness into the context of a longer period of strong share price gains. Expectations around the company’s ability to grow...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 10%, nearly mirroring the S&P 500.

ALHC's AI and automation are boosting margins and efficiency, but CMS risk model changes and revenue timing cloud near-term earnings visibility.

PACS vs. ALHC: Which Stock Is the Better Value Option?

SCAN Health Plan and Alignment Healthcare both filed lawsuits against the CMS last week after regulators refused to recalculate industry-wide MA scores using the same methodology as for Clover Health.